Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases

About this course

• Released:
• Expires: March 30, 2028

Target Audience

This activity is intended for practicing dermatologists and other physicians involved in the treatment and management of diseases of the skin.

Learning Objective

Patients using glucocorticoids should be carefully monitored for glycaemic control, especially those with pre-existing type 2 diabetes mellitus or impaired glucose tolerance. • The relationship between glucocorticoid dose and the onset of type 2 diabetes mellitus is unclear. Therefore, patients who have not previously experienced complications still require careful monitoring. • There is insufficient evidence to suggest ‘pulse’ regimens, low daily doses or use of different steroidal agents can prevent onset of hyperglycaemic complications. • The benefit of glucocorticoid use should be balanced against the risk of adverse events, including complications outside of type 2 diabetes. • Consider the use of adjuvant or alternative therapies that are not associated with hyperglycaemic adverse effects where suitable.

Accreditation and Designation Statement

Once the test is passed, a certificate of completion will be generated. The learning activity can be added to the Royal College of Physicians' CPD diary as a self-certified entry.

Activity Disclosures

No commercial support has been accepted related to the development or publication of this activity.